SE444172B - PROCEDURE FOR PREPARING PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS OF 1-N-ETHYLSISOMICINE - Google Patents
PROCEDURE FOR PREPARING PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS OF 1-N-ETHYLSISOMICINEInfo
- Publication number
- SE444172B SE444172B SE7805684A SE7805684A SE444172B SE 444172 B SE444172 B SE 444172B SE 7805684 A SE7805684 A SE 7805684A SE 7805684 A SE7805684 A SE 7805684A SE 444172 B SE444172 B SE 444172B
- Authority
- SE
- Sweden
- Prior art keywords
- acid addition
- addition salts
- ethylsisomicine
- procedure
- acceptable acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
- C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
- C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
- C07H15/234—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
- C07H15/236—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2 a saccharide radical being substituted by an alkylamino radical in position 3 and by two substituents different from hydrogen in position 4, e.g. gentamicin complex, sisomicin, verdamycin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
7805684-3 Salterna framställes enligt kända metoder, såsom genom neutralisering av den fria basen med ifrågavarande syra till ungefär pH 5. Lämpliga syror för detta ändamål omfattar sådana som saltsyra, svavelsyra, fosforsyra, salpetersyra/ bromvätesyra, ättiksyra, propion" syra, maleinsyra, askorbinsyra, citronsyra och liknande. Fysikaliskt karakteriseras syraadditionssalterna av föreningarna enligt uppfin- ningen såsom vita fasta substanser, vilka är lösliga i vatten, svår- lösliga i flertalet polära lösningsmedel och olösliga i icke-polära organiska lösningsmedel. The salts are prepared by known methods, such as by neutralizing the free base with the acid in question to about pH 5. Suitable acids for this purpose include those such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid / hydrobromic acid, acetic acid, propionic acid, maleic acid, ascorbic acid, citric acid, etc. Physically, the acid addition salts of the compounds of the invention are characterized as white solids, which are soluble in water, sparingly soluble in most polar solvents and insoluble in non-polar organic solvents.
Föreliggande föreningar utgör bredspektrum-antibakteriella medel som på ett fördelaktigt sätt uppvisar aktivitet mot många orga- Q nismer, särskilt gramnegativa organismer, vilka är resistenta mot deras l-N-osubstituerade prekursorer. De kan således användas separat eller i kombination med andra antibiotiska medel för förhindrande av tillväxten eller reduktion av antalet bakterier i olika miljöer. De ka: exempelvis användas direkt för desinfektion av laboratorieglas, dental och medicinsk apparatur förorenad med Staphylococcus aureus eller andra bakterier, kan inhiberas av de enligt uppfinningen erhållna före ningarna. Aktiviteten av föreningarna mot gramnegativa bakterier gör g dessa föreningar ænënüxma för bekämpning av infektioner, förorsakade: av gramnegativa bakterier, såsom arter av Proteus och Pseudomonas. A De har veterinärmedicinsk användning, särskilt vid behandling av mastit hos nötkreatur och Salmonella-inducerad diarre hos husdjur, C såsom hos hund och katt.The present compounds constitute broad-spectrum antibacterial agents which advantageously exhibit activity against many organisms, especially gram-negative organisms, which are resistant to their 1-N-unsubstituted precursors. Thus, they can be used separately or in combination with other antibiotics to prevent the growth or reduction of the number of bacteria in different environments. They can: for example, be used directly for disinfection of laboratory glass, dental and medical equipment contaminated with Staphylococcus aureus or other bacteria, can be inhibited by the compounds obtained according to the invention. The activity of the compounds against gram-negative bacteria makes these compounds extremely effective in controlling infections caused by gram-negative bacteria, such as species of Proteus and Pseudomonas. A They have veterinary use, especially in the treatment of mastitis in cattle and Salmonella-induced diarrhea in domestic animals, C such as in dogs and cats.
Utgångsmaterialet för förfarandet enligt uppfinningen kan framställas enligt kända metoder ur sisomicin. l-N-etylering av sisomicin utföres företrädesvis genom omsättning med acetaldehyd i närvaro av ett reduktionsmedel, såsom visas i exempel 1.The starting material for the process according to the invention can be prepared according to known methods from sisomycin. 1-N-ethylation of sisomicin is preferably carried out by reaction with acetaldehyde in the presence of a reducing agent, as shown in Example 1.
Exempel l. l-N-etylsisomicin En lösning av 5 g sisomicin i 250 ml vatten försättes med IN svavelsyra, tills pH i lösningen inställts på ungefär 5. Den bildaf de lösningen av sisomicinsvavelsyraadditionssalt försättes med 0,85 gå natriumcyanborhydrid. Fortsätt omröringen 15 minuter vid rumstempera-É tur, koncentrera lösningen i vakuum till en volym av ungefär 100 ml, É behandla lösningen med ett basiskt jonbytarharts [såsom Amberlite J I IRA 4015 (OH-)] och lyofilisera till en återstod, omfattande 1-N-style sisomicin. g 7805684-3 É 3 Rena genom kromatografering på 200 g silika, eluera med den lägre fasen av systemet kloroform/metanol/7%-ig ammoniumhydroxid 2 (2:l:l). Kombinera lika eluat, såsom fastställes genom tunnskikts- kromatografering och koncentrera de kombinerade eluaten av huvud- komponenten i vakuum till en återstod, omfattande l-N-etyl-sisomicin (utbyte 1,25 g). Rena åter genom kromatografering på 100 g silikagel och eluera med systemet kloroform/metanol/3,5%-ig ammoniumhydroxid (1:2:1). Låt de kombinerade, likadana eluaten (såsom fastställes genon tunnskiktskromatografering) passera genom en pelare av basiskt jon- bytarharts och lyofilisera eluatet för bildning av l-N-etylsisomicin 3 (utbyte o,s4 9), [a1š6 +1s4° (0,3 s, a2o); PMR (ppm) (n2o)= _;1,os f (3H, t, J = 782, -CH2C§3); 1,19 (3H« ä, -C-C§3); 2,5 (3H, s, N-CQ3), 1 4,85 (IH, m, =C§-); 4,95 (lH, d, J = 4Hz, Hl”); 5,33 (lä, d, J = 2,5H¿ H1'). + * Masspektrum: (M+l) m/e 476 också m/e 127, 154, 160, 173, 191, 201, 219, 256, 299, 317, 332, 345, 350, 360, 378, 390, 400.Example 1. 1-N-ethylsisomicin A solution of 5 g of sisomicin in 250 ml of water is added with 1N sulfuric acid, until the pH of the solution is adjusted to about 5. The resulting solution of sisomicin sulfuric acid addition salt is added with 0.85 g of sodium cyanoborohydride. Continue stirring for 15 minutes at room temperature, concentrate the solution in vacuo to a volume of about 100 ml, treat the solution with a basic ion exchange resin [such as Amberlite JI IRA 4015 (OH-)] and lyophilize to a residue, comprising 1-N -style sisomycin. g 7805684-3 É 3 Purify by chromatography on 200 g of silica, eluting with the lower phase of the system chloroform / methanol / 7% ammonium hydroxide 2 (2: 1: 1). Combine equal eluate, as determined by thin layer chromatography, and concentrate the combined eluates of the major component in vacuo to a residue, comprising 1-N-ethyl-sisomicin (yield 1.25 g). Purify again by chromatography on 100 g of silica gel eluting with the system chloroform / methanol / 3.5% ammonium hydroxide (1: 2: 1). Pass the combined, similar eluates (as determined by thin layer chromatography) through a column of basic ion exchange resin and lyophilize the eluate to give 1N-ethylsisomicin 3 (yield o, s4 9), [a1š6 + 1s4 ° (0.3 s, a2o); PMR (ppm) (n20) = _; 1, os f (3H, t, J = 782, -CH2C§3); 1.19 (3H, δ, -C-C§3); 2.5 (3H, s, N-CQ3), 1.85 (1H, m, = C§-); 4.95 (1H, d, J = 4Hz, H1); 5.33 (lä, d, J = 2.5H¿ H1 '). + * Mass spectrum: (M + 1) m / e 476 also m / e 127, 154, 160, 173, 191, 201, 219, 256, 299, 317, 332, 345, 350, 360, 378, 390, 400 .
Exempel 2. Syraadditionssalter Svavelsyraadditionssalter av l-N-etylsisomicin Lös 5,0 g l-N-etylsisomicin i 25 ml vatten och inställ pH i lösningen på 4,5 med lN svavelsyra. Häll lösningen i ungefär 300 ml metanol under kraftig omröring, fortsätt omröringen ungefär 10-20 minuter och filtrera. Tvätta fällningen med metanol och torka vid ungefär 600 i vakuum för bildning av 1-N-etylsisomicinsulfat.Example 2. Acid addition salts Sulfuric acid addition salts of 1-N-ethylsisomicin Dissolve 5.0 g of 1-N-ethylsisomicin in 25 ml of water and adjust the pH of the solution to 4.5 with 1N sulfuric acid. Pour the solution into about 300 ml of methanol while stirring vigorously, continue stirring for about 10-20 minutes and filter. Wash the precipitate with methanol and dry at about 600 in vacuo to give 1-N-ethylsisomicin sulfate.
NMR-spektrum för 1-N-etylsisomicinsulfatg 20-% (vikt/volym) lösning i denteriumoxid med natrium-2,2-dimetyl-2-sila-pentan-S-sulfonat så-: . ~ o som inre referens: 20 C Proton Kemisk förskjutning Intensitet Multiplicitet ötppm) 1-NHCHZCH3 1,33 3H tripletu;J = 7Hz 4”-CH3 " 1,35 3H singlett 2,3 1,67 - 2,83 I 48 multipletter 3"-xacaa 2,93 L sa singleæz 1-NHCH CR 3_18 _ ZH kvartett; J - 7Hz 2 3 7805684-3 3. 5”-axial 2. 1" 4. 1.NMR spectrum of 1-N-ethylsisomicin sulphate g 20% (w / v) solution in denteric oxide with sodium 2,2-dimethyl-2-sila-pentane-S-sulfonate so-:. ~ o as internal reference: 20 C Proton Chemical shift Intensity Multiplicity ötppm) 1-NHCHZCH3 1.33 3H triplet; J = 7Hz 4 "-CH3" 1.35 3H singlet 2.3 1.67 - 2.83 In 48 multiplets 3 "-xacaa 2.93 L sa singleæz 1-NHCH CR 3_18 _ ZH quartet; J - 7Hz 2 3 7805684-3 3. 5 ”-axial 2. 1" 4. 1.
HDO 3:45 3,47 1H 18 18 18 1H dublett: J dublett, J dublett av J = 4Hz, dublettï J J multiplett dublettz J 11HZ 12Rz dubletter 10Bz 4Hz 1,5Hz lf _ \ v. ha. A ;f'.'»ïÄ5;§i-».ÃÉÄ;'~:?WÉÉI:«HDO 3:45 3.47 1H 18 18 18 1H doublet: J doublet, J doublet of J = 4Hz, doubletï J J multiplet doubletz J 11HZ 12Rz doublets 10Bz 4Hz 1.5Hz lf _ \ v. Ha. A; f '.' »ÏÄ5; §i -». ÃÉÄ; '~:? HOW: «
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38575173A | 1973-08-06 | 1973-08-06 | |
US45260074A | 1974-03-19 | 1974-03-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
SE7805684L SE7805684L (en) | 1978-05-17 |
SE444172B true SE444172B (en) | 1986-03-24 |
Family
ID=27011126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE7805684A SE444172B (en) | 1973-08-06 | 1978-05-17 | PROCEDURE FOR PREPARING PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS OF 1-N-ETHYLSISOMICINE |
Country Status (3)
Country | Link |
---|---|
DK (1) | DK150202C (en) |
FR (1) | FR2305190A1 (en) |
SE (1) | SE444172B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4298690A (en) * | 1977-05-19 | 1981-11-03 | Kyowa Hakko Kogyo Co., Ltd. | Antibiotics XK-62-3 and XK-62-4 and process for production thereof |
DE2924659A1 (en) * | 1979-06-19 | 1981-01-22 | Bayer Ag | PSEUDOTRISACCHARIDE, THEIR PRODUCTION AND USE AS A MEDICINAL PRODUCT |
-
1976
- 1976-05-10 FR FR7613947A patent/FR2305190A1/en active Granted
-
1978
- 1978-05-17 SE SE7805684A patent/SE444172B/en not_active IP Right Cessation
-
1979
- 1979-02-08 DK DK052779A patent/DK150202C/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK150202C (en) | 1987-06-22 |
FR2305190B1 (en) | 1980-12-05 |
DK52779A (en) | 1979-02-08 |
DK150202B (en) | 1987-01-05 |
FR2305190A1 (en) | 1976-10-22 |
SE7805684L (en) | 1978-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kavanagh et al. | Antibiotic Substances from Basidiomycetes: IX. Drosophila Subtarata.(Batsch Ex Fr.) Quel. | |
DE2437160C3 (en) | 1-N-ethylsisomicin and salts, processes for their preparation and pharmaceutical preparations containing these compounds | |
CA2077562A1 (en) | Diastereomers of 1-(isopropoxycarbonyloxy) ethyl 3-cephem-4-carboxylate and processes for their preparation | |
SE444172B (en) | PROCEDURE FOR PREPARING PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS OF 1-N-ETHYLSISOMICINE | |
DE1948943C2 (en) | Medicaments containing D-α-sulfobenzylpenicillin | |
US20080221076A1 (en) | Crystalline Sodium Salt of Cephalosporin Antibiotic | |
DE2203653B2 (en) | 3-Carbamoyloxymethyl-7- (2-thienylacetamido) -3-cephem-4-carboxylic acid and its salts, processes for the preparation of these compounds and medicaments containing such compounds | |
FI62843C (en) | FOERFARANDE FOER FRAMSTAELLNING AV ETT SYRAADDITIONSSALT AV 1 - ETYLSISOMICIN | |
US4426393A (en) | Method of protecting useful plants and formulations for use in said method | |
NO171502C (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE THIADIAZOLYLACETAMIDE CEFEM DERIVATIVES | |
DE1795508C (en) | 6- (alpha-aminoacylamino) -penicillanic acid derivatives. Elimination from: 144 5419 | |
RU2672472C1 (en) | Substituted aminobenzopentatiepines as antimicrobial agents | |
JPS54125672A (en) | Pseudomonic acid amide derivative, or its salt, and their preparation | |
US3852264A (en) | Gentamicin c oxazolidine derivatives | |
US4243801A (en) | 6"-Amino derivatives of 4-0-aminoglycosyl-6-0-garosaminyl-1,3-diaminocyclitols | |
FI66876C (en) | FOERFARANDE FOER FRAMSTAELLNING AV ANTIBAKTERIELLT AKTIV 7BETA (SYN-2-METOXY-IMINO-2- (2-AMINO-4-THIAZOLYL) ACETAMIDO) -3- (1- (2-SULFAMINOETHYL)) TETRAZOL-5-YLTI -4-carboxylic acid | |
CH586708A5 (en) | ||
DE1793628C (en) | Erythromycin oxime and process for its preparation | |
DE1241943B (en) | Method of Obtaining Lincomycin B | |
DE1543831C (en) | Process for the preparation of Erythromy cinglutamate | |
RU1797489C (en) | Method of respiration diseases treatment in calves | |
DE2112058A1 (en) | Chemical compounds and processes for their preparation | |
SU1632390A1 (en) | Gametocyde for rye | |
AT263210B (en) | Process for the preparation of new 6-deoxytetracycline derivatives | |
SU782317A1 (en) | 1,2-dibenzoylpyruvoyl-hydrazine exhibiting antimicrobial activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NUG | Patent has lapsed |
Ref document number: 7805684-3 Effective date: 19940910 Format of ref document f/p: F |